Have you been diagnosed with a neuroendocrine cancer that has not responded to other treatment options? If so then you may be eligible to participate in a study to examine the safety and effectiveness of a new cancer therapy designed to target specific neuroendocrine tumors cells.

The purpose of this study is to interview breast cancer survivors in North Carolina to understand how various factors have impacted their emotional well-being

Have you been diagnosed with cancer? If so, you may have the opportunity to participate in a research study designed to examine how central oncology navigation affects the use of supportive care services. Additionally, the study will assess whether enrollment in non-treatment clinical trials increases with the implementation of an Oncology Navigation Resource (ORN) intervention.

Do you have a new diagnosis of Leukemia? If so, you may be able to take part in a research study on a new drug called Quizartinib. We want to see if this new drug helps treat Leukemia better. Compensation provided.

Do you have T-cell Lymphoma? Is your disease relapsed or refractory and CD5 positive? If so, you may be able to participate in this gene therapy research study to learn more about using your own modified immune cells as possible treatment.

Do you have incurable, metastatic/recurrent head and neck squamous cell carcinoma? If so, you may be able to take part in a study to see if a new drug called petosemtamab is effective. We want to see if petosemtamab works better than the treatments doctors usually use for head and neck squamous cell carcinoma. Compensation provided.

Have you had an organ transplant or hematopoietic cell transplant and have advanced cutaneous squamous cell carcinoma? If so, you might be eligible to take part in a study to see if an investigation drug, RP1, can help treat your skin cancer.

In this study, we want to asses the long-term safety of using a virus to deliver a gene, AAV2-hAQP1, and how effective this gene is at treating dry mouth in people who have received radiation therapy for head and neck cancer.

In this study, we want to see what happens when one of the drugs in a 4-drug combination called Dara-RVd is given once a week instead of twice a week. We will look at how this timing change affects the outcome of multiple myeloma with autologous stem cell transplantation. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

Have you been diagnosed with Stage III non-small cell lung cancer? Is your cancer advanced and not able to to removed? If so, you might be able to participate in a study that looks at a study drug to see if it can help the radiation treatment work better against your cancer.